Five-Year Survival Rates for Prostate Cancer by Stage
For all stages combined, the 5-year relative survival rate for prostate cancer is 97%, with localized disease approaching 100%, regional disease exceeding 90%, and distant metastatic disease at 37% 1, 2.
Survival by Stage at Diagnosis
Localized Disease
- 5-year survival: Nearly 100% 2
- Represents approximately 75% of cases at diagnosis 2
- Age-standardized 5-year net survival for localized disease was >90% in recent Japanese data (2010-2014) 3
- 10-year relative survival for localized stage was 100% in U.S. data (2001-2016) 4
Regional Disease
- 5-year survival: >90% 3
- Accounts for approximately 11-14% of cases at diagnosis 2, 4
- Represents lymph node involvement without distant metastases
Distant/Metastatic Disease
- 5-year survival: 37% 2
- Represents approximately 5-10% of cases at diagnosis 2, 4
- Survival has improved over time: from 28.7% (2001-2005) to 32.3% (2011-2016) 4
- Japanese data shows 47.3% 5-year net survival for distant metastasis (2010-2014) 3
Important Racial and Ethnic Disparities
Significant survival disparities exist by race/ethnicity, particularly for distant-stage disease 4:
For distant-stage prostate cancer (2001-2016), 5-year survival varies substantially:
- Asian/Pacific Islander: 42.0% (highest)
- Hispanic: 37.2%
- American Indian/Alaska Native: 32.2%
- Black men: 31.6%
- White men: 29.1% (lowest for distant disease)
Black men face double the prostate cancer mortality compared to White men, despite only 67% higher incidence 5. American Indian/Alaska Native men have 12% higher mortality despite 13% lower incidence 5.
Critical Trends and Clinical Implications
The incidence of distant-stage disease is increasing rapidly, particularly concerning in younger men 5:
- Men <55 years: 2.6% annual increase in distant-stage disease
- Men 55-69 years: 6.0% annual increase
- Men ≥70 years: 6.2% annual increase
This reversal from declining to increasing incidence (3.0% annually during 2014-2021) largely reflects changes in PSA screening practices following the 2012 USPSTF recommendations against routine testing 1, 5.
Age-Related Survival Considerations
Prognosis is poorest for patients aged ≥75 years 6. The excellent overall survival statistics are heavily influenced by the high proportion (75%) of patients diagnosed with localized disease, for which survival approaches 100% 3.
Common Pitfalls
- Lead-time bias: The comparatively low death rate is complicated by screening-related lead-time bias and detection of indolent cancers 1
- Stage migration: Reduced screening has led to more advanced disease at diagnosis, threatening maintenance of historically low death rates 1
- Racial disparities in stage at diagnosis: American Indian/Alaska Native, Asian American/Pacific Islander, and Hispanic men are less likely to be diagnosed with localized disease (64%-67%) compared to Black and White men (71%-72%) 5